<DOC>
	<DOCNO>NCT00085176</DOCNO>
	<brief_summary>RATIONALE : Cancer therapy may affect ability child 's brain central nervous system function normally . Learning identify patient develop complication may improve ability doctor plan cancer treatment improve patient quality life . PURPOSE : This clinical trial study neurobehavioral change child receive steroid therapy intrathecal therapy acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Neurobehavioral Complications Children Who Were Previously Treated With Steroids Intrathecal Therapy Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Compare neurobehavioral functioning , specifically memory , attention , executive function , visual-motor integration , process speed , child previously treat steroid ( prednisone v dexamethasone ) intrathecal therapy ( methotrexate alone vs methotrexate , cytarabine , hydrocortisone ) childhood acute lymphoblastic leukemia . - Correlate non-treatment risk factor , gender , age diagnosis , time since termination prior therapy , impaired neurobehavioral function patient . - Correlate neurobehavioral complication quality-of-life patient . OUTLINE : This multicenter , cohort study . Patients assign 1 2 cohort ( prior treatment per CCG-1922 [ prednisone v dexamethasone ] v prior treatment per CCG-1952 [ intrathecal ( IT ) methotrexate v IT methotrexate , cytarabine , hydrocortisone ] ) . Patients cohort stratify accord age diagnosis , gender , time since prior treatment termination . - Cohort A ( CCG-1922 ) : Patients undergo physical neurological examination , neurobehavioral evaluation , quality life assessment . Neurobehavioral evaluation assess memory , attention , executive function . - Cohort B ( CCG-1952 ) : Patients undergo evaluation . Neurobehavioral evaluation ass visual-motor integration process speed . PROJECTED ACCRUAL : A total 448 patient ( 224 per cohort ) accrue study within 4 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis standardrisk childhood acute lymphoblastic leukemia ( ALL ) In continuous first remission No history CNS pathology require radiotherapy surgery Prior enrollment one follow Children 's Cancer Group ( CCG ) protocol AND terminate therapy least 1 year ago : CCG1922 ( prednisone v dexamethasone ) CCG1952 ( intrathecal methotrexate v triple intrathecal therapy ) No prior enrollment CCG1952 arm III No history preexist neurodevelopmental disorder diagnosis ALL ( e.g. , mental retardation , Down syndrome , seizure disorder , traumatic brain injury ) No neuropsychological assessment within past 6 month PATIENT CHARACTERISTICS : Age 6.5 16 year Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Other Reading , speaking , listen comprehension English patient require ( English and/or Spanish parent ) No history low birth weight ( &lt; 1,500 gram ) PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics Endocrine therapy See Disease Characteristics Radiotherapy See Disease Characteristics Surgery See Disease Characteristics Other Concurrent stimulant allow</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>long-term effect secondary cancer therapy child</keyword>
	<keyword>neurotoxicity</keyword>
	<keyword>psychosocial effect cancer treatment</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
</DOC>